Consolidated Guidelines
Geneva, 2016
The End TB Strategy
Thousands of HIV-positive Venezuelans have been forced to leave the country, after facing discrimination and zero treatment options, according to UNAIDS.
Patients once received free ARV treatment under Venezuela’s National AIDS Program. In 2017, the country essentially ran out of ARVs—about 9 p...eople a day died from HIV-related illnesses that year.
“Today, HIV patients in Venezuela have three options: go untreated, buy the medication abroad or on the black market for large sums, or leave the country,” writes Gabriela Mesones Rojo.
The exodus of untreated Venezuelans could shift the course of the epidemic throughout the region.
more
Directrices
Grupos de población clave
2016 Update
Key population
Guidelines
Key Populations
WHO Annual Meeting with Pharmaceutical Companies and Stakeholders
08 March 2016, Geneva
2015-06-03 - Board presentation - v32.pptx
Par ses propriétés thérapeutiques, le médicament permet aux professionnels de santé
ainsi quaux pouvoirs publics dassurer la santé des populations. De ce fait, sa disponibilité et
son efficacité sont essentielles et sont le résultat dun circuit complexe (de sa fabrication... à sa
destruction en passant par sa distribution).
Laccessibilité au médicament est un élément déterminant de toute politique de santé.
Elle est garantie par la politique pharmaceutique de chaque pays qui vise à rendre le
médicament disponible pour tous, sur lensemble du territoire (accessibilité géographique), à
tout moment (accessibilité physique), à un prix abordable (accessibilité financière) et en
garantissant son efficacité et sa qualité (accessibilité qualitative
more
Agodokpessi et al. Journal of Pharmaceutical Policy and Practice (2015) 8:12DOI 10.1186/s40545-015-0033-7
Benin established a revolving drug fund (RDF) for essential asthma medicines in 2008. We evaluated
the operation of the RDF and assessed whether there was interruption of supply of asthma me...dicine from 2008 to
2013.
more
HIV drug resistance , Users Manual
December 2017
The aim of the operational framework is to ensure 1) accurate collection, handling, shipment and storage of specimens collected in countries implementing HIV drug resistance surveillance; and 2) the availability of quality-assured HIV genotyping laboratory services producing comparable and reliable ...results at the national, regional and global levels.
This publication updates the WHO HIVResNet HIV drug resistance laboratory operational framework published in 2017 and reflects technical and strategic developments over the past three years.
more
12-13 December 2016
Global Action Plan on HIV Drug Resistance - Webinars 12-13 December 2016
WHO
Considering programmatic implications of rising levels of HIV drug resistance: finalizing the Global Action Plan
Webinars 12 13 Dec 2016
Guidelines
June 2017
HIV strategic information for impact